专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

4. 发明申请

US20090220949A1 Mutations Associated with the Long QT Syndrome and Diagnostic Use Thereof 审中-公开
标题翻译：与长QT综合征相关的突变及其诊断用途
公开(公告)号：US20090220949A1
公开(公告)日：2009-09-03
申请号：US11916791
申请日：2006-06-07
申请人： Silvia Giuliana Priori
发明人： Silvia Giuliana Priori
IPC分类号： C12Q1/68 , B01D57/02
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156
摘要： The present invention is based on the identification of new mutations in KCNQ1 (also termed KvLQTI), KCNH2 (also termed HERG), SCN5A, KCNE1 (also termed minK), KCNE2 (also termed MiRP) genes that encode ionic channels involved in cardiac electrical activity and are potentially responsible for the Long QT Syndrome. According to a main aspect, the invention relates to nucleic acids, oligonucleotides and polynucleotides and mRNA, containing sequences of KCNQ1, KCNH2 SCN5A, KCNE1, KCNE2 genes and cDNAs in a mutated form and to respective variant proteins thereof. A preferred embodiment of the present invention is represented by a diagnostic method based on the identification of a group of about 70 non-private mutations in the KCNQ1, KCNH2 and SCN5A genes, detected at high frequency. The method, which is able to identify about 40% of the probands, is non exclusively based on identification of mutations that are described and characterized in this invention where said identification has both prognostic and diagnostic value for the Long QT Syndrome.
摘要翻译：本发明基于鉴定KCNQ1（也称为KvLQTI），KCNH2（也称为HERG），SCN5A，KCNE1（也称为minK），KCNE2（也称为MiRP）基因的新突变，其编码涉及心电的离子通道活动，并可能对长QT综合征负责。根据主要方面，本发明涉及包含KCNQ1，KCNH2 SCN5A，KCNE1，KCNE2基因和突变形式的cDNA及其各自变体蛋白质的序列的核酸，寡核苷酸和多核苷酸和mRNA。本发明的优选实施方案以基于鉴定在高频检测的KCNQ1，KCNH2和SCN5A基因中约70个非私人突变的组的诊断方法表示。能够鉴定约40％的先证者的方法不仅仅基于本发明描述和表征的突变的鉴定，其中所述鉴定对于长QT综合征具有预后和诊断价值。

5. 发明申请

US20050143927A1 Method for estimating or predicting the anti-tumor activity of a compound and for estimating or predicting the tumor growth in mammals 审中-公开
标题翻译：用于估计或预测化合物的抗肿瘤活性并用于估计或预测哺乳动物肿瘤生长的方法
公开(公告)号：US20050143927A1
公开(公告)日：2005-06-30
申请号：US10941459
申请日：2004-09-15
申请人： Cristiano Cammia , Giuseppe DeNicolao , Italo Poggesi , Maurizio Rocchetti
发明人： Cristiano Cammia , Giuseppe DeNicolao , Italo Poggesi , Maurizio Rocchetti
IPC分类号： G06F19/00
CPC分类号： G06F19/3456 , G06F19/321 , G16H50/50
摘要： The present invention relates to a method for estimating or predicting anti-tumor activity of a compound and for estimating or predicting the tumor growth in mammals; the estimation comprises a) measuring the tumor weight in time; b) measuring the concentration of the compound in time; c) calculating kinetic parameters of the tumor growth: -a parameter (L0), representative of the portion of tumor cells present at the instant t0=0 that succeeds in taking root and in starting tumor cells proliferation in the mammals; -an index (λ0) of the production rate of tumor cells during an exponential phase of tumor growth; -an index (λ1) of tumor cells mass produced in the time unit during a linear phase of the tumor growth; and pharmacodynamic parameters: -an index (K1) of tumor cells death rate; -an index (K2) of the potency of the compound; and d) calculating tumor growth curves.
摘要翻译：本发明涉及一种用于估计或预测化合物的抗肿瘤活性并估计或预测哺乳动物肿瘤生长的方法; 估计包括：a）及时测量肿瘤重量; b）及时测定化合物的浓度; c）计算肿瘤生长的动力学参数：-a参数（L 0 O 0），其表示在时间t 0 0 0 = 0处存在的部分肿瘤细胞，其成功在哺乳动物中起根和起始肿瘤细胞增殖; - 肿瘤生长指数期肿瘤细胞产生率的指标（λ<0> 0 ）; - 在肿瘤生长的线性期间以时间单位产生的肿瘤细胞块的指数（λ1 N 1）; 和药效学参数： - 肿瘤细胞死亡率的指标（K 1 N 1）; - 化合物的效力的指数（K 2 N 2）; 和d）计算肿瘤生长曲线。

6. 发明公开

US20240131220A1 SILK FIBROIN BIOINKS AND RELATED USE FOR 3D BIOPRINTING 审中-公开
公开(公告)号：US20240131220A1
公开(公告)日：2024-04-25
申请号：US18278082
申请日：2022-02-24
申请人： UNIVERSITA' DEGLI STUDI DI PAVIA , CELLINK
发明人： Alessandra BALDUINI , Christian Andrea DI BUDUO , Pierre-Alexandre LAURENT , Erik GATENHOLM , Hector MARTINEZ , Itedale REDWAN-NAMRO , Volodymyr KUZMENKO
IPC分类号： A61L27/26 , A61L27/38 , A61L27/54 , B33Y10/00 , B33Y70/00 , B33Y80/00 , C08L5/04 , C08L89/04
CPC分类号： A61L27/26 , A61L27/3834 , A61L27/54 , B33Y10/00 , B33Y70/00 , B33Y80/00 , C08L5/04 , C08L89/04 , A61L2300/254 , A61L2300/256 , A61L2300/414 , A61L2300/64
摘要： The present invention relates to silk fibroin bioinks specifically formulated for use in 3D bioprinting and the production of ex-vivo models capable of supporting hematopoiesis and the production of platelets and blood cells.

7. 发明申请

US20220001620A1 PHOTOSENSITIVE COMPOSITION FOR 3D PRINTING 有权
公开(公告)号：US20220001620A1
公开(公告)日：2022-01-06
申请号：US17285715
申请日：2018-10-16
申请人： UNIVERSITA' DEGLI STUDI DI PAVIA
发明人： Daniele DONDI
IPC分类号： B29C64/314 , B33Y40/10 , B33Y70/00 , C07C67/08 , C08K5/23 , C08G63/78 , C08G63/02 , C08F226/10
摘要： A process for producing a photosensitive resin for 3D printing includes: (i) treating a vegetable oil with a polyol to form a monoglyceride, (ii) reacting the monoglyceride of step (i) with an unsaturated reagent to form a liquid resin with viscosity lower than 20 Pa·s at the temperature of 20° C., and (iii) mixing the liquid resin with a comonomer and a photoinitiator, as well as the photosensitive resin for 3D printing obtainable from such process and the 3D object obtainable from such photosensitive resin.

8. 发明授权

US07241592B2 Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use 有权
标题翻译：来自胶原蛋白结合蛋白的交叉反应置换抗体及鉴定和使用方法
公开(公告)号：US07241592B2
公开(公告)日：2007-07-10
申请号：US09810428
申请日：2001-03-19
申请人： Magnus Hook , Yi Xu , Pietro Speziale , Livia Visal , Fabrizia Casolini , Joseph M. Patti , Pratiksha Patel , Paul Domanski
发明人： Magnus Hook , Yi Xu , Pietro Speziale , Livia Visal , Fabrizia Casolini , Joseph M. Patti , Pratiksha Patel , Paul Domanski
IPC分类号： C12P21/08 , C12N1/00 , A61K39/395 , A61K39/40 , C07K16/12
CPC分类号： C07K16/1271 , A61K39/085 , A61K2039/505 , C07K2317/76 , C07K2317/92 , C07K2319/00 , G01N33/56938 , G01N2333/31 , G01N2333/78 , G01N2500/00
摘要： Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermidis bacteria and which can thus be used in the prevention and treatment of infections caused by both of these types of bacteria. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the proteins are advantageous because they are cross-reactive and may thus be administered to patients so as to reduce or prevent severe infection by staphylococcal bacteria of more than one species. Antibodies generated in this manner have also been shown to exhibit displacement activity and can thus be utilized advantageously in methods wherein these antibodies will be administered to patients having pre-existing staphylococcal infections because of the ability to displace bacterial proteins from binding sites on the extracellular matrix. Finally, a method of identifying, isolating and utilizing displacing antibodies is also provided.
摘要翻译：提供了对CNA蛋白和来自胶原结合结构域的其他区域（包括结构域CNA19）的抗体，并且以这种方式产生的抗体已显示与金黄色葡萄球菌和表皮葡萄球菌交叉反应，因此可以用于预防和治疗由这两种细菌引起的感染。此外，可以使用本发明的抗体治疗医疗器械，以便减少或消除它们被感染或进一步扩散感染的可能性。特别地，蛋白质是有利的，因为它们是交叉反应性的，并且因此可以施用于患者，以便减少或预防多于一种物种的葡萄球菌细菌的严重感染。以这种方式产生的抗体也已显示出显示置换活性，因此可有利地用于其中将这些抗体施用于具有预先存在的葡萄球菌感染的患者的方法，因为能够从细胞外基质上的结合位点置换细菌蛋白质。最后，还提供了鉴定，分离和利用置换抗体的方法。

9. 发明授权

US10435450B2 MET receptor agonist proteins 有权
公开(公告)号：US10435450B2
公开(公告)日：2019-10-08
申请号：US15544710
申请日：2016-01-21
申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT PASTEUR DE LILLE , UNIVERSITA' DEGLI STUDI DI PAVIA , UNIVERSITÉ DE LILLE
发明人： Jerome Vicogne , Oleg Melnyk , Nathalie Ollivier , Eric Adriaenssens , Berenice Leclercq , Claire Simonneau , Giovanni De Nola , Ermanno Gherardi , Hugo De Jonge
IPC分类号： C07K14/475 , C12N15/63 , A61K38/18 , A61K38/00
摘要： Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.

10. 发明授权

US08211432B2 Treatment of Staphylococcus aureus infections utilizing antibodies that bind to fibronectin binding proteins 有权
标题翻译：使用结合纤连蛋白结合蛋白的抗体治疗金黄色葡萄球菌感染
公开(公告)号：US08211432B2
公开(公告)日：2012-07-03
申请号：US11589760
申请日：2006-10-31
申请人： Magnus Höök , Joseph M. Patti , Karen L. House-Pompeo , Pietro Speziale , Danny Joh , Martin J. McGavin
发明人： Magnus Höök , Joseph M. Patti , Karen L. House-Pompeo , Pietro Speziale , Danny Joh , Martin J. McGavin
IPC分类号： A61K39/395 , C07K16/18
CPC分类号： A61K39/085 , A61K38/00 , A61K39/00 , A61K39/092 , A61K2039/505 , C07K14/31 , C07K14/315 , C07K16/1271 , C07K16/1275 , C07K2317/34 , C07K2317/54 , C07K2317/76 , C07K2319/00 , G01N33/6887 , G01N2333/31 , G01N2333/315 , G01N2333/78
摘要： Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnbA and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments encoding these peptides and epitopes. The anti-(fibronectin binding site) antibodies, peptides and epitopes that give rise to antibodies that block the binding of fibronectin binding proteins to fibronectin, and DNA segments encoding these proteins and are of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of streptococcal and staphylococcal colonization in animals or humans. These. DNA segments and the peptides derived therefrom are proposed to be of use directly in the preparation of vaccines and also for use as carrier proteins in vaccine formulations.
摘要翻译：公开了阻断纤连蛋白与纤连蛋白结合的抗体。还公开了衍生自金黄色葡萄球菌的fnbA和fnbB基因的位点特异性突变和截短的肽表位，失语链球菌的fnbA和fnbB基因，以及化脓性链球菌的sfb基因，以及编码这些肽和表位的核酸片段。产生阻断纤连蛋白结合蛋白与纤连蛋白结合的抗体的抗（纤连蛋白结合位点）抗体，肽和表位，以及编码这些蛋白质的DNA片段，并且可用于各种筛选，诊断和治疗应用，包括活性和被动免疫和预防动物或人类中链球菌和葡萄球菌定居的方法。这些。提出DNA段及其衍生的肽直接用于疫苗的制备，也可用作疫苗制剂中的载体蛋白。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式